These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25595963)

  • 1. Outcome of salvage treatment for recurrent glioblastoma.
    Kim HR; Kim KH; Kong DS; Seol HJ; Nam DH; Lim DH; Lee JI
    J Clin Neurosci; 2015 Mar; 22(3):468-73. PubMed ID: 25595963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma: patterns of recurrence and efficacy of salvage treatments.
    Oh J; Sahgal A; Sanghera P; Tsao MN; Davey P; Lam K; Symons S; Aviv R; Perry JR
    Can J Neurol Sci; 2011 Jul; 38(4):621-5. PubMed ID: 21672702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients.
    Vinjamuri M; Adumala RR; Altaha R; Hobbs GR; Crowell EB
    J Neurooncol; 2009 Jan; 91(2):221-5. PubMed ID: 18813874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
    Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
    Oh SW; Jee TK; Kong DS; Nam DH; Lee JI; Seol HJ
    Acta Neurochir (Wien); 2014 Apr; 156(4):641-51. PubMed ID: 24553726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
    Conti A; Pontoriero A; Arpa D; Siragusa C; Tomasello C; Romanelli P; Cardali S; Granata F; De Renzis C; Tomasello F
    Acta Neurochir (Wien); 2012 Feb; 154(2):203-9. PubMed ID: 21984132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.
    Azoulay M; Santos F; Shenouda G; Petrecca K; Oweida A; Guiot MC; Owen S; Panet-Raymond V; Souhami L; Abdulkarim BS
    J Neurooncol; 2017 May; 132(3):419-426. PubMed ID: 28374095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
    Faustino AC; Viani GA; Hamamura AC
    Clinics (Sao Paulo); 2020; 75():e1553. PubMed ID: 32935821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
    Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
    Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection.
    Elliott RE; Parker EC; Rush SC; Kalhorn SP; Moshel YA; Narayana A; Donahue B; Golfinos JG
    World Neurosurg; 2011; 76(1-2):128-40; discussion 61-2. PubMed ID: 21839964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
    Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
    J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
    Goda JS; Lewis S; Agarwal A; Epari S; Churi S; Padmavati A; Gupta T; Shetty P; Moiyadi A; Jalali R
    Clin Neurol Neurosurg; 2015 Aug; 135():46-53. PubMed ID: 26038275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
    McNamara MG; Lwin Z; Jiang H; Chung C; Millar BA; Sahgal A; Laperriere N; Mason WP
    J Neurooncol; 2014 Mar; 117(1):153-60. PubMed ID: 24469855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.